Navigation Links
Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Date:5/19/2009

First Patent to be Issued from Among Intradigm's Large Collection of Pending siRNA Sequence Patents

PALO ALTO, Calif., May 19 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases." The issued patent covers a specific double-stranded siRNA sequence that is directed against the angiogenic pathway and which possesses therapeutic potential in the treatment of cancer. This is the first patent to be issued to Intradigm related to an active pharmaceutical ingredient in the RNAi space and is one of a significant number of pending patent applications worldwide covering proprietary Intradigm siRNA sequences against more than 50 clinically relevant targets.

As Intradigm's first issued piece of intellectual property (IP) related to an active pharmaceutical ingredient, this patent supplements the company's existing patent portfolio, providing Intradigm issued IP in each of the three essential areas of RNAi therapeutic development: target sequences, delivery and siRNA structural features. Based on this broad IP portfolio, Intradigm is in a uniquely strong position within the RNAi therapeutic industry, particularly among other private companies in the space.

"With the continued rapid maturation of the RNAi industry, it is critical that Intradigm properly protect the breakthroughs that are being pioneered in our labs. As we continue to take important steps to execute our strategy, we find ourselves in the enviable position of possessing one of the industry's broadest and strongest RNAi IP portfolios," said Philip Haworth, chief executive officer of Intradigm. "With today's development, we have further broadened and strengthened this position and can now claim to have a portfolio that contains issued patents in all three of our RNAi therapeutic areas of focus."

"While the issuance of this important patent is cause for excitement on its own, the broader message regarding the potential of Intradigm's siRNA sequence IP is particularly gratifying," said Mike Riley, Intradigm's vice president of intellectual property and corporate development. "Based on today's patent issuance, we have a great deal of confidence concerning the large number of pending sequence-specific patent applications currently under review worldwide. Each subsequent patent issuance related to an active pharmaceutical ingredient will only serve to further strengthen Intradigm's position of leadership in the RNAi therapeutic space."

Intradigm possesses one of the industry's strongest RNAi IP positions including key assets strategically licensed from both the University of Massachusetts Medical School and the Massachusetts Institute of Technology (MIT). The company's IP estate of issued patents and pending applications broadly covers structural features for a next generation of RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics, and proprietary siRNA sequence applications.

ABOUT INTRADIGM

Intradigm is a private biotechnology company committed to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases with an initial focus on oncology. Intradigm is unique among private companies, with its comprehensive RNAi therapeutics platform consisting of structural features for a next generation of RNAi molecules, biodegradable polycationic polymers for the delivery of RNAi therapeutics and proprietary siRNA sequences. Our proprietary delivery technology is unique in its potential to offer safe and effective systemic administration using a library of novel peptide-based biodegradable polymers.

We have established an impressive proprietary portfolio of siRNA sequences against more than 50 highly valued oncology and other disease targets. In addition, we have secured an exclusive license to the Zamore patent family from the University of Massachusetts, which covers broad structural features of siRNA design for more potent next generation siRNA sequences. Our goal is to grow Intradigm to become a leading company in enabling the development of novel RNAi therapeutics against a broad range of therapeutic targets using our extensive internally developed know-how and our comprehensive IP estate.

For more information on Intradigm, please visit www.intradigm.com.


'/>"/>
SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards
2. NxStage Announces Strategic Business Alliance with Asahi Kasei Kuraray Medical
3. Beckman Coulter, Inc. Announces Common Stock Offering
4. Games for Health Conference Announces First Cognitive Health Track Powered by SharpBrains
5. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
6. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
7. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
8. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
9. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
10. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
11. International Student Insurance Announces Website Redesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... The OSHA Training Center at Chabot-Las ... headquartered in Northern California, has issued an important reminder to employers to prevent ... Employers with workers exposed to high temperatures should establish a complete heat illness ...
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media with ... X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice Color ... users can now reveal the media of their split screens with growing colorful ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced today its affiliation with Tennessee Counseling Association. This new relationship ... of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , "TCA ...
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/26/2016)...  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ) reported ... required to build a strong and stable market for ... on the OTC Markets-pink current trading platform. ... are seeing an anomaly in market trading activities that ... the Company, but shareholders and market players as well. ...
Breaking Medicine Technology: